GeneCopoeia’s Lentifect™ SARS-CoV-2 Spike-pseudotyped lentivirus products produce a specially-packaged version of standard lentivirus, whereby the vesicular stomatitis G (VSV-G) envelope glycoprotein is replaced by the Spike (S) protein from SARS-CoV-2, the virus responsible for the COVID-19 pandemic. These particles, also known as “pseudoviruses”, are typically used to infect cultured cells expressing ACE2, the receptor for SARS-CoV-2 on multiple tissue types (Figure 1).
Lentifect™ SARS-CoV-2 Spike-pseudotyped lentivirus and our ACE2- and TMPRSS2-expressing cell lines are great for several applications in a safe environment without the use of pathogenic SARS-CoV-2 viruses, such as:
- Assessment of the efficacy of vaccines against SARS-CoV-2 virus variants
- Studying the efficacy and mechanism of neutralizing antibodies against SARS-CoV-2 virus variants
- Development of antiviral therapeutic agents
- Studying the mechanism of virus-receptor interaction
Lentifect™ SARS-CoV-2 Spike-pseudotyped lentivirus products are part of GeneCopoeia’s COVID-19 Coronavirus Research Tools products. Note: Spike-pseudotyped lentiviruses are for research purposes only. They are not intended for diagnostic or treatment usage in humans.
Ordering information
Use the drop-down menus below to view products for lentivirus packaged with SARS-CoV-2 Spike protein.
For more information, please contact inquiry@genecopoeia.com.
GeneCopoeia has produced HEK293T cell lines expressing human ACE2 alone, or ACE2 in combination with TMPRSS2, a protease that promotes Spike-ACE2 receptor interaction. These cell lines express ACE2 and/or TMPRRSS2 mRNA at high levels (Figure 1). Due to display of ACE2 protein (Figure 2) and/or TMPRSS2 protein ((Figure 3) on the cell surface, these cells are amenable to infection by viruses expressing SARS-CoV-2 Spike protein in their envelopes.
You can order these cell lines from the table below. To obtain the datasheet for each cell line, please click on the designated catalog number.
In addition to the products below, custom stable cell lines are also available. For more information, please contact inquiry@genecopoeia.com.
For more information or to request a quote, please contact inquiry@genecopoeia.com.
Performance data
Figure 1. Relative mRNA expression levels of ACE2 and TMPRSS2 in GeneCopoeia stable cell lines. mRNA was amplified via RT-qPCR using primers specific for each gene. Ct values of ACE2 and TMPRSS2 were normalized to Ct values for housekeeping gene GAPDH. Relative expression levels were calculated from 2^ΔΔCt. A. ACE2 mRNA expression in parental cell line HEK293T and ACE2-overexpressing HEK293T cell line SL221. B. ACE2 and TMPRSS2 mRNA expression in parental cell line HEK293T and ACE2- and TMPRSS2-overexpressing cell line SL222.
Figure 2. Immunofluorescence (IF) analysis of ACE2 protein expression on the cell surface of ACE2-expressing HEK293T cells (Cat.# SL221), ACE2/TMPRSS2 expressing HEK293T cells (Cat.# SL222), and HEK293T cells. Unpermeablized cells were fixed, blocked and incubated with the primary anti-ACE2 antibody, then washed and incubated with fluorescent-labeled secondary antibody, washed again, and stained with DAPI.
Figure 3. Immunofluorescence (IF) analysis of TMPRSS2 protein expression on the cell surface of TMPRSS2-expressing HEK293T cells (Cat.# SL222), and HEK293T cells. Unpermeablized cells were fixed, blocked and incubated with the primary anti-TMPRSS2 antibody, then washed and incubated with fluorescent-labeled secondary antibody, washed again, and stained with DAPI.
